Flag of the European Union EU Clinical Trials Register Help

Clinical trials for b

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12,936 result(s) found for: b. Displaying page 644 of 647.
    «« First « Previous 639  640  641  642  643  644  645  646  647  Next»
    EudraCT Number: 2009-009858-24 Sponsor Protocol Number: CINC424A2352 Start Date*: 2009-05-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment-II
    Medical condition: Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) SE (Completed) FR (Completed) DE (Completed) AT (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021231-14 Sponsor Protocol Number: A1501095 Start Date*: Information not available in EudraCT
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE SAFETY, TOLERABILITY, AND EFFICACY OF VORICONAZOLE AND ANIDULAFUNGIN IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF INVA...
    Medical condition: Primary therapy of invasive aspergillosis (IA) in pediatric subjects aged 2 to 17 years.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003488 Aspergillosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) FR (Ongoing) NL (Ongoing) DK (Prematurely Ended) PL (Completed) DE (Prematurely Ended) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2010-020602-14 Sponsor Protocol Number: CCD-1005-PR-0040 Start Date*: 2012-04-23
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A 12-WEEK, MULTINATIONAL, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, 2-ARM PARALLEL GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF CHF 1535 200/6µg (FIXED COMBINATION BECLOMETHASONE DIP...
    Medical condition: ADULTS ASTHMATIC PATIENTS NOT ADEQUATELY CONTROLLED ON HIGH DOSES OF INHALED CORTICOSTEROIDS OR ON MEDIUM DOSE OF INHALED CORTICOSTEROIDS PLUS LONG-ACTING β2 AGONISTS
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) CZ (Completed) IT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-005225-54 Sponsor Protocol Number: 248.615 Start Date*: 2006-07-10
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A phase IV randomised, double-blind, placebo-controlled, dose titration trial with pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/day per os for 12 weeks to investigate the effects on RLS symptoms...
    Medical condition: Restless Legs Syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058920 pref
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) FI (Completed) DK (Completed) ES (Completed) IT (Completed) SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006431-42 Sponsor Protocol Number: 248.629 Start Date*: 2007-05-30
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A phase IV randomised, double-blind, placebo-controlled, dose titration trial with pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/day per os to investigate the long-term efficacy, safety and toler...
    Medical condition: Restless Legs Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058920 Restless legs syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) FI (Completed) IE (Completed) BE (Completed) AT (Completed) GR (Prematurely Ended) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-020363-21 Sponsor Protocol Number: SGN35-010 Start Date*: 2010-11-09
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: An open-label, phase 2/3, treatment-option protocol of brentuximab vedotin in patients with progression of Hodgkin lymphoma
    Medical condition: Patients who were on the placebo arm and experienced progression of HL while participating in the SGN35-005 clinical study
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020328 Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) ES (Completed) IT (Completed) BG (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001989-41 Sponsor Protocol Number: 26866138-MMY-3002 Start Date*: 2004-12-13
    Sponsor Name:Janssen-Cilag Kft.
    Full Title: An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone versus Melphalan/Prednisone in subjects with previously untreated Multiple Myeloma.
    Medical condition: First-Line Multiple Myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) AT (Completed) CZ (Completed) IE (Completed) GB (Completed) DE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000325-21 Sponsor Protocol Number: A6181122 Start Date*: 2007-05-02
    Sponsor Name:Pfizer Inc. - 235 East 42nd Street - New York - 10017
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFIRI) AS FIRST LINE TREATMENT
    Medical condition: first-line treatment of patients with metastatic colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Completed) DE (Completed) AT (Completed) ES (Completed) HU (Completed) BE (Completed) PT (Completed) CZ (Completed) GB (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2008-000854-11 Sponsor Protocol Number: H80-MC-GWCH Start Date*: 2008-09-26
    Sponsor Name:Eli Lilly and Company
    Full Title: Safety and Efficacy of Exenatide Once Weekly Injection versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients with Type 2 Diabetes
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) SK (Completed) ES (Completed) FR (Completed) DE (Completed) IT (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002626-23 Sponsor Protocol Number: CRFB002A2411 Start Date*: 2013-11-26
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A 12-month, phase IIIb, randomized, visual acuity, assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen,...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) BE (Completed) DE (Completed) SK (Completed) GB (Completed) HU (Completed) PT (Completed) DK (Completed) SI (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2005-004023-19 Sponsor Protocol Number: A0081046 Start Date*: 2006-05-25
    Sponsor Name:Pfizer Ltd, Ramsgate Rd, Sandwich, Kent, United Kingdom
    Full Title: A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN (LYRICA) AND LAMOTRIGINE (LAMICTAL) IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES
    Medical condition: Epilepsy; Patients with newly diagnosed partial seizures (with or without secondary generalization)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061334 Partial seizures LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) PT (Completed) ES (Completed) BE (Completed) IE (Completed) CZ (Completed) LT (Completed) DE (Completed) SK (Completed) IT (Completed) HU (Completed) FI (Completed) EE (Completed) BG (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2006-003560-62 Sponsor Protocol Number: R092670PSY3006 Start Date*: 2007-03-28
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects with Schi...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) EE (Completed) LT (Completed) DE (Completed) AT (Completed) FR (Completed) CZ (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-002111-82 Sponsor Protocol Number: 42603ATT3013 Start Date*: 2007-10-24
    Sponsor Name:Janssen-Cilag International N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) i...
    Medical condition: Attention Deficit-Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) NL (Completed) DK (Completed) FI (Completed) BE (Completed) GB (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004140-23 Sponsor Protocol Number: 27298 Start Date*: 2007-06-06
    Sponsor Name:Merck Serono Int, a branch of Laboratoires Serono SA an affiliate of Merck KGaA, Darmstadt, Germany
    Full Title: A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa anta...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) BE (Completed) BG (Completed) PT (Completed) ES (Completed) GR (Completed) IT (Completed) NL (Completed) SE (Completed) FI (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-018001-51 Sponsor Protocol Number: ING111762 Start Date*: 2010-11-10
    Sponsor Name:Viiv Healthcare S. L
    Full Title: Estudio de Fase III aleatorizado, doble ciego, para evaluar la seguridad y eficacia de 50 mg una vez al día de GSK1349572 frente a 400 mg dos veces al día de Raltegravir, ambos administrados en com...
    Medical condition: Sujetos adultos infectados por el VIH-1, que han recibido tratamiento antirretroviral previo con la excepción de un inhibidor de la integrasa.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008922 Chronic infection with HIV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) BE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) GR (Completed) IT (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-002780-27 Sponsor Protocol Number: GAL-ALZ-3005 Start Date*: 2008-08-26
    Sponsor Name:Janssen Cilag International NV
    Full Title: A Randomized, Double-blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-severe Alzheimer’s Disease
    Medical condition: Mild to moderately severe Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) LT (Completed) LV (Prematurely Ended) EE (Prematurely Ended) CZ (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) AT (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2009-018070-64 Sponsor Protocol Number: 28431754DIA3012 Start Date*: 2010-05-12
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26 Week Multicenter Study with a 26-Week Extension to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 (Canagli...
    Medical condition: Type 2 Diabetes Mellitus With Inadequate Glycemic Control
    Disease: Version SOC Term Classification Code Term Level
    12.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (Completed) DE (Completed) PT (Prematurely Ended) FR (Completed) ES (Completed) IT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014290-40 Sponsor Protocol Number: DU176b-D-U305 Start Date*: 2010-02-10
    Sponsor Name:Daiichi Sankyo Development Limited
    Full Title: A phase 3, randomized, double-blind, double-dummy, parallel-group, multi-center, multi-national study for the evaluation of efficacy and safety of (LMW) heparin/edoxaban versus (LMW) heparin/warfar...
    Medical condition: Reduction of the risk of symptomatic recurrent venous thromboembolic complications in patients with acute symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    14.1 10047065 - Vascular disorders 10051055 Deep vein thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) SE (Completed) FR (Completed) EE (Completed) BE (Completed) AT (Completed) ES (Completed) DK (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002522-29 Sponsor Protocol Number: 352.2046 Start Date*: 2008-10-08
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: A randomised, double-blind, active-controlled study to evaluate the impact of stepwise withdrawal of inhaled corticosteroid treatment in patients with severe to very severe chronic obstructive pulm...
    Medical condition: Chronic obstructive pulmonary disease (COPD). Enfermedad Pulmonar Obstructiva Crónica.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) BE (Completed) DE (Completed) GB (Completed) DK (Completed) NL (Completed) HU (Completed) IT (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-003784-32 Sponsor Protocol Number: 20050201 Start Date*: 2007-05-02
    Sponsor Name:Amgen Inc
    Full Title: A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer
    Medical condition: Subjects with unresectable stage IIIB with pericardial or pleural effusion or stage IV or recurrent Non Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) ES (Completed) AT (Completed) FR (Completed) CZ (Completed) DE (Completed) HU (Completed) IT (Completed) GR (Completed) SK (Completed) BG (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 639  640  641  642  643  644  645  646  647  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 17:11:00 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA